Enhancing PDAC Therapy: Decitabine-Olaparib Synergy Targets KRAS-Dependent Tumors
G. Anastasio, M. Felaco, A. Lamolinara, F. Del Pizzo, E. Cacciagrano, C. Mottini, M. Mutarelli, F. Di Modugno, M. Iezzi, L. Cardone
This paper shows that low-dose decitabine combined with olaparib enhances antitumor activity in KRAS-dependent pancreatic ductal adenocarcinoma, regardless of BRCA1/2 status.
bioRxiv · Jun 23, 2024Cancer Biology